NovoCure Aktie [WKN DE: A140ML / ISIN: JE00BYSS4X48]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu NovoCure Limited

08.07.23		ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
03.07.23		Novocure to Report Second Quarter 2023 Financial Results (Businesswire)
01.07.23		ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages NovoCure Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
24.06.23		ROSEN, LEADING TRIAL ATTORNEYS, Encourages NovoCure Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
01.06.23		Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education (Businesswire)
04.05.23		Novocure Reports First Quarter 2023 Financial Results (Businesswire)
26.04.23		Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Businesswire)
14.04.23		Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023 (Businesswire)
03.04.23		Novocure to Report First Quarter 2023 Financial Results (Businesswire)
29.03.23		Kristin Stafford Joins Novocure Board of Directors (Businesswire)
16.03.23		Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program (Businesswire)
01.03.23		Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France (Businesswire)
01.03.23		Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer (Businesswire)
23.02.23		Allyson J. Ocean, M.D., Joins Novocure Board of Directors (Businesswire)
23.02.23		Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update (Businesswire)
15.02.23		Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer (Businesswire)
19.01.23		Novocure Announces Organizational Changes to Prepare for Future Growth (Businesswire)
10.01.23		Novocure: LUNAR-Studie erreicht primären Endpunkt für Gesamtüberleben bei nicht kleinzelligem Lungenkrebs (Businesswire)
09.01.23		Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update (Businesswire)
05.01.23		Zai Lab And Novocure Announce LUNAR Study Meets Primary Endpoint (RTTNews)
05.01.23		Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint (Businesswire)
27.12.22		Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
29.11.22		Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma (Businesswire)
23.11.22		Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference (Businesswire)
17.11.22		Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting (Businesswire)
15.11.22		Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada (Businesswire)
11.11.22		Novocure Secures CE Mark for New Array (Businesswire)
27.10.22		Novocure Reports Third Quarter 2022 Financial Results (Businesswire)
22.10.22		Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting (Businesswire)
20.10.22		Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology (Businesswire)
20.10.22		Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy (Businesswire)
03.10.22		Novocure to Report Third Quarter 2022 Financial Results (Businesswire)
21.09.22		Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business (Businesswire)
31.08.22		Novocure to Participate in Upcoming Investor Conferences (Businesswire)
10.08.22		Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility (Businesswire)
29.07.22		Alnylam Q2 Loss Widens, SGEN Boosts Revenue Outlook, NVCR To Report LUNAR Study Data In Q1 (RTTNews)
28.07.22		Novocure Reports Second Quarter 2022 Financial Results (Businesswire)
27.07.22		Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program (Businesswire)
01.07.22		Novocure to Report Second Quarter 2022 Financial Results (Businesswire)
21.06.22		Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer (Businesswire)
03.06.22		Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer (Businesswire)
26.05.22		Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma (Businesswire)
29.04.22		ACCD Guides Q1 Well Below Analysts' Estimates, ALNY Cuts Outlook, NVCR Braces For Busy Year (RTTNews)
28.04.22		Novocure Reports First Quarter 2022 Financial Results (Businesswire)
19.04.22		Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu (Businesswire)
08.04.22		Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields (Businesswire)
01.04.22		Novocure to Report First Quarter 2022 Financial Results (Businesswire)
24.03.22		Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial (Businesswire)
23.03.22		Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer (Businesswire)
28.02.22		Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

Krypto-Update: Diese fünf Kryptowährungen stehen derzeit im Fokus

Bitcoin überholt Silber: Kryptowährung auf Rekordkurs

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

Diese Aktien empfehlen Experten zu kaufen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	25.11.2024 23:29
Kaufwert:	EUR
	Hinzufügen Speichern